Dallas, Texas-based Vaxxinity, under the direction of CEO Mei Mei Hu, JD and Chief Medical Officer Ulo Palm, uses synthetic peptides to mimic and optimally combine biological epitopes to selectively activate the immune system and overcome “immune tolerance”, or the body’s tendency to avoid attacking molecules within your own body. Traditional vaccine technologies have to date fallen short in attempts to achieve this due to insufficient responses and side effects. The platform has been scientifically validated, with billions of doses commercialized in animal health, and 6 human clinical trials successfully completed. Vaxxinity is developing an anti-tau product candidate that has the potential to address multiple neurodegenerative conditions, including AD, by targeting abnormal tau proteins alone and in potential combination with other pathological proteins such as Aβ to combat multiple pathological processes at once. Currently in preclinical trials.